US · Healthcare · Medical Devices
EPS came in at -0.19 against a street estimate of -0.26 — a beat of 26.9%.
Analysts rate Pulmonx Corp a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $3.70.
CONFIDENT Pulmonx returned to global revenue growth, cut losses sharply, and reiterated 2026 revenue guidance while rebuilding U.S. commercial momentum. Q3 FY26 China shipments are expected to resume by early 2027; China represents about 2% of business. Analysts focused on U.S. sales productivity, 2027 growth drivers, spending discipline, sales-force expansion, and cash-burn reduction. Management emphasized execution, stable costs, and gradual productivity gains. 2026-10-27…
Full summary in the app.
| Fund | Stake |
|---|---|
| PRIMECAP Management Company | 10.74% |
| Morgan Stanley - Brokerage Accounts | 6.81% |
| Soleus Capital Management, L.P. | 6.49% |
| Vanguard Capital Management, LLC | 3.80% |
| ExodusPoint Capital Management, LP | 2.85% |
| Almitas Capital LLC | 2.48% |
| BlackRock Inc | 2.05% |
| Stonepine Capital Management Llc | 1.90% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pulmonx Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.